Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx

Apr 19 2012

Related Content

Onyx Walks Away From Option To Develop SBIO JAK2 Inhibitors; SBIO CEO Looks To Chart A New Course

May 04 2011

Incyte’s <em>Jakafi</em> Gets Broad Label, Early Approval For Myelofibrosis

Nov 16 2011

Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors

Jan 07 2009

Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review

Jan 30 2012

Related Companies

CTI BioPharma Corp.

Incyte Corporation

Onyx Pharmaceuticals, Inc.

Additional Topics

Singapore Asia Pacific United States Europe Clinical Trials Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window